-
GlycoNex Reaches Major Milestone with Japanese Regulatory Submission for Denosumab Biosimilar
A New Step Forward for Biosimilar Access GlycoNex Inc. has officially announced a significant milestone in its product development pipeline. The company has successfully submitted a New Drug Application (NDA) to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for SPD8, their highly anticipated denosumab biosimilar. Understanding the Significance of SPD8 Denosumab is a…
-
GMP Labeling Celebrates 40 Years of US Manufacturing for Regulated Industries
GRANITE BAY, Calif., Oct. 1, 2026 /PRNewswire/ — As pharmaceutical and biotechnology sectors navigate evolving global supply chain risks, GMP Labeling Inc. is utilizing Manufacturing Day 2026 to highlight its nearly 40-year history as a domestic manufacturer of critical compliance… Source: Read More
-
Genomma Lab Internacional Secures Strategic Long-Term Debt Financing
Strengthening Financial Foundations Genomma Lab Internacional, a prominent player in the pharmaceutical and personal care industry, has officially announced the completion of a significant long-term debt transaction. This strategic financial maneuver is designed to bolster the company’s capital structure and support its ongoing operational objectives. Key Details of the Transaction The company has utilized this…
-
Evonik Bolsters Global Biotech Footprint with New Vancouver GMP Facility
A Major Leap for Lipid-Based Drug Delivery Evonik has officially strengthened its position in the pharmaceutical manufacturing sector with the expansion of its lipid-based drug delivery capabilities. The company has announced the establishment of a new Good Manufacturing Practice (GMP) facility located in Vancouver, Canada, marking a significant milestone in their strategy to support the…
-
Soligenix | Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet’s Disease
NASDAQ: SNGX Introduction to Soligenix’s Phase 2 Clinical Trial Soligenix, a biopharmaceutical company focused on developing innovative therapies, has recently received FDA Investigational New Drug (IND) clearance for the Phase 2 clinical trial of Dusquetide in the treatment of aphthous ulcers in Behçets Disease. This clearance marks a significant milestone in the development of potential…